Eli Lilly and Company LLY
will present Phase II data in rheumatoid arthritis (RA) for two of its
investigational autoimmune medicines at the annual meeting of the American
College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in
Washington, D.C. These compounds include tabalumab, an anti-BAFF monoclonal
antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in
partnership with Incyte Corporation.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in